Coquí Pharma is making its presence known in the radiopharmaceuticals industry, creating a scalable and reliable domestic supply of Mo-99 to ensure that patients have access to the low-cost diagnostics and treatments they need, when they need them.
The Mo-99 Challenge
Molybdenum-99 (Mo-99) is the world’s most widely used medical radioisotope. Radioisotopes are used in imaging and scanning technologies (like SPECT and PET scans) to diagnosis and treat diseases. With no domestic production and global shortages caused by the shutdown of aging nuclear reactors, the U.S. faces a great challenge in securing a reliable source of Mo-99 needed for lifesaving diagnostics and treatment.
Why Coquí Pharma?
Coquí Pharma has the proven technology, using a previously FDA approved process, and expert know-how to ensure the U.S. has a reliable domestic supply of Mo-99. Coquí Pharma is building a dedicated Medical Isotope Production Facility, the first of its kind in the U.S., to produce a commercially scalable and reliable source of medical diagnostic and therapeutic radioisotopes.
Coquí Pharma’s mission is to create a commercially scalable and reliable supply of medical diagnostic and therapeutic radioisotopes in the U.S. using proven technology.
“Coquí is not reinventing the wheel. We are streamlining the Mo-99 production process, so the U.S. has a readily available supply of medical radioisotopes, with greater access and lower costs for patients who need them.”
— Carmen I. Bigles, President and CEO of Coquí Pharma